• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SD filed by Clene Inc.

    5/22/26 4:43:43 PM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CLNN alert in real time by email
    SD 1 clnn20260324_sd.htm FORM SD clnn20260324_sd.htm

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549


    FORM SD

    SPECIALIZED DISCLOSURE REPORT


    CLENE INC.

    (Exact name of registrant as specified in its charter)


     

    Delaware

    001-39834

    85-2828339

    (State or other jurisdiction of

    (Commission File Number)

    (I.R.S. Employer
    incorporation or organization)   Identification No.)
         

    6550 South Millrock Drive, Suite G50

    Salt Lake City, Utah

      84121
    (Address of principal executive offices)   (Zip code)

     

    Jerry Miraglia, (443) 273-1645

    (Name and telephone number, including area code,

    of the person to contact in connection with this report.)

     

    Check the appropriate box to indicate the rule pursuant to which this Form is being submitted, and provide the period to which the information in this Form applies:

     

    ☒

    Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2025.

     

    ☐

    Rule 13q-1 under the Securities Exchange Act (17 CFR 240.13q-1) for the fiscal year ended December 31, 2025.

     

     

     

     

    Section 1 – Conflict Minerals Disclosure

     

    Item 1.01 Conflict Minerals Disclosure and Report

     

    This Specialized Disclosure Form of Clene Inc. (the “Company”) is being filed in accordance with Rule 13p-1 (the “Rule”) under the Securities Exchange Act of 1934, as amended, for the reporting period from January 1, 2025 to December 31, 2025 (the “Relevant Period”). The Rule imposes disclosure requirements of certain information when a company manufactures or contracts to manufacture products for which Conflict Minerals are necessary to the functionality or production of those products. The term “Conflict Minerals” means columbite-tantalite (coltan), cassiterite, gold, wolframite, or their derivatives, which are limited to tantalum, tin, and tungsten, or any other mineral or its derivatives determined by the Secretary of State to be financing conflict in the Democratic Republic of the Congo or an adjoining country (the “Covered Countries”).

     

    During the Relevant Period, the Company determined a Conflict Mineral, gold, was necessary to the functionality or production of its products.

     

    Conflict Minerals Disclosure

     

    The Company conducted a reasonable country of origin inquiry regarding the origin of gold used in its products during the Relevant Period. The Company’s reasonable country of origin inquiry consisted of (i) identifying all suppliers of gold to the Company, which consisted of one supplier during the Relevant Period, (ii) requesting that each gold supplier complete the Responsible Minerals Initiative (“RMI”) Conflict Minerals Reporting Template (“CMRT”), a standardized reporting template developed by RMI to collect sourcing information on Conflict Minerals, and (iii) reviewing the supplier response and CMRT and performing any follow-up procedures or clarification as deemed necessary. The Company received a response from its gold supplier which included 45 other smelters that it sourced gold from during the Relevant Period, which the Company cross-referenced against the RMI Conformant Smelter List without exception. The RMI Conformant Smelter List is a list of smelters who have successfully completed an independent, third-party audit assessment of smelter and refiner management systems and sourcing practices for responsible mineral procurement against Responsible Minerals Assurance Process standards. Based on the information obtained from these procedures, the Company has no reason to believe that any of the gold sourced during the Relevant Period originated in any of the Covered Countries. Therefore, in accordance with the Rule, the Company is not required to conduct a due diligence process or file a Conflict Minerals Report with respect to such conflict minerals. The Company’s only obligation is to briefly describe both the reasonable country of origin inquiry it undertook and the corresponding results as set forth hereinabove.

     

    This Conflict Minerals Disclosure is publicly available on the Company’s website, located at https://invest.clene.com/financial-information/sec-filings. The information contained in or accessible from the Company’s website is not incorporated into this Form SD and should not be considered part of this Form SD.

     

    Item 1.02 Exhibit

     

    Not applicable.

     

    Section 2 – Resource Extraction Issuer Disclosure

     

    Item 2.01 Resource Extraction Issuer Disclosure and Report

     

    Not applicable.

     

    Section 3 – Exhibits

     

    Item 3.01 Exhibits

     

    Not applicable.

     

    1

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the duly authorized undersigned.

     

     

    CLENE INC.

     

     

     

     

     

    Date: May 22, 2026

    By:

    /s/ Robert Etherington

     

     

     

    Robert Etherington

     

     

     

    President and Chief Executive Officer

     

     

    2
     
    Get the next $CLNN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CLNN

    DatePrice TargetRatingAnalyst
    10/4/2022Outperform → Perform
    Oppenheimer
    7/18/2022$16.00Buy
    H.C. Wainwright
    5/2/2022$10.00Buy
    Canaccord Genuity
    9/28/2021$20.00Outperform
    Oppenheimer
    More analyst ratings

    $CLNN
    SEC Filings

    View All

    SEC Form SD filed by Clene Inc.

    SD - Clene Inc. (0001822791) (Filer)

    5/22/26 4:43:43 PM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Clene Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - Clene Inc. (0001822791) (Filer)

    5/22/26 4:37:23 PM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Clene Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Clene Inc. (0001822791) (Filer)

    5/14/26 8:02:05 AM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLNN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Clene Reports First Quarter 2026 Financial Results and Recent Operating Highlights

    After successful completion of FDA Type C meeting, Clene expects to submit an NDA for CNM-Au8® under the accelerated approval pathway in the third quarter of 2026In January 2026, Clene completed an oversubscribed registered direct offering totaling over $28 million, including an initial tranche of more than $6 million and two additional tranches totaling over $22 million tied to regulatory milestones In May 2026, Clene amended its existing $10 million convertible debt facility, extending maturity by six months to August 2027 and eliminating required monthly principal and interest payments before maturityIn May 2026, Clene completed a $7 million underwritten registered direct offering with a

    5/14/26 8:00:00 AM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Presenting on Emerging Growth Conference 92 Day 2 on May 7; Register to live stream

    MIAMI, May 06, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 92nd Emerging Growth Conference on May 6 & 7, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: Questions@EmergingGrowth.com For updates, follow us on Twitter. Presenting today – Wednesday, May 6, 2026 9:00Virtual Lobby opens.Register for the Conference. If you already registered, go

    5/6/26 7:00:00 AM ET
    $ATCH
    $CLNN
    $CRGO
    Finance: Consumer Services
    Finance
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Clene Announces $7 Million Underwritten Offering of Common Stock

    SALT LAKE CITY, May 05, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN) (along with its subsidiaries, "Clene" or the "Company") and its wholly owned subsidiary, Clene Nanomedicine, Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced the pricing of an underwritten registered direct offering of 1,000,000 shares of common stock at a purchase price of $7.00 per share to a single investor.   The gross proceeds from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses, are

    5/5/26 8:45:00 AM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLNN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Matlin David J bought $216,664 worth of shares (33,333 units at $6.50), increasing direct ownership by 7% to 477,824 units (SEC Form 4)

    4 - Clene Inc. (0001822791) (Issuer)

    1/13/26 2:48:54 PM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Matlin David J bought $438,458 worth of shares (92,307 units at $4.75), increasing direct ownership by 26% to 444,491 units (SEC Form 4)

    4 - Clene Inc. (0001822791) (Issuer)

    10/2/24 12:58:21 PM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Science Officer Mortenson Mark bought $97,432 worth of shares (20,512 units at $4.75), increasing direct ownership by 243% to 28,949 units (SEC Form 4)

    4 - Clene Inc. (0001822791) (Issuer)

    10/1/24 4:17:45 PM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLNN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Mclaughlin Vallerie

    4 - Clene Inc. (0001822791) (Issuer)

    5/22/26 2:03:40 PM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Desai Arjun Jj

    4 - Clene Inc. (0001822791) (Issuer)

    5/22/26 2:02:42 PM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Mosca Alison

    4 - Clene Inc. (0001822791) (Issuer)

    5/22/26 2:02:03 PM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLNN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Clene downgraded by Oppenheimer

    Oppenheimer downgraded Clene from Outperform to Perform

    10/4/22 8:58:30 AM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Clene with a new price target

    H.C. Wainwright initiated coverage of Clene with a rating of Buy and set a new price target of $16.00

    7/18/22 7:19:07 AM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Canaccord Genuity initiated coverage on Clene with a new price target

    Canaccord Genuity initiated coverage of Clene with a rating of Buy and set a new price target of $10.00

    5/2/22 9:11:11 AM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLNN
    Leadership Updates

    Live Leadership Updates

    View All

    Clene Appoints Neurology Expert to Executive Team

    SALT LAKE CITY, March 16, 2023 (GLOBE NEWSWIRE) -- Clene, Inc. (NASDAQ:CLNN) along with its subsidiaries "Clene" and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, today announced the appointment of Benjamin Greenberg, M.D., M.H.S. as Head of Medical.    An internationally recognized expert in treating disorders of the central nervous system, Dr. Greenberg brings extensive clinical and research experience to Clene as the company continues its development of CNM-Au8® as a potential treatment for amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). "Dr. Green

    3/16/23 9:46:10 AM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Clene Announces New Chief Financial Officer Morgan Brown

    SALT LAKE CITY, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN) along with its subsidiaries "Clene" and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, today announced the appointment of Morgan Brown as Chief Financial Officer effective Feb. 1, 2022. "Morgan joins the executive team at a pivotal time in Clene's growth," stated Clene's President and CEO, Rob Etherington. "He is a seasoned healthcare executive and public-company biopharma CFO, who has led the out-licensing of commercial stage assets and M&A transactions as well as numerous substantial equity and

    2/1/22 7:00:00 AM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Clene Nanomedicine Appoints Dr. Vallerie McLaughlin to its Board of Directors

    SALT LAKE CITY, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN) along with its subsidiaries "Clene" and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company dedicated to the treatment of neurodegenerative disease using nanotechnology to treat energetic failure, today announced the appointment of Vallerie V. McLaughlin, MD, to its board as its seventh independent director. Dr. McLaughlin is the Kim A. Eagle MD Endowed Professor of Cardiovascular Medicine, Associate Chief Clinical Officer for Cardiovascular Services of the University of Michigan Medical Group, Associate Chief, Division of Cardiovascular Medicine, and Director of the Pulm

    8/5/21 4:01:00 PM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLNN
    Financials

    Live finance-specific insights

    View All

    Clene Announces Statistically Significant ALS Biomarker Results Supporting Accelerated Approval Pathway for CNM-Au8®

    FDA recommended biomarker analyses show statistically significant reductions in NfL and GFAP in participants treated with CNM-Au8Biomarker improvements are strongly associated with longer survival, reinforcing CNM-Au8's potential disease modifying activityCompany has requested a Type C meeting in the first quarter of 2026 to present the newly completed analyses supporting a planned NDA submission under the accelerated approval pathwayClene is hosting an investor webcast today at 8:30 am ET SALT LAKE CITY, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN) (along with its subsidiaries, "Clene" or the "Company") and its wholly owned subsidiary Clene Nanomedicine, Inc., a late clinic

    12/3/25 8:00:00 AM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Clene Reports Topline Results Demonstrating Survival Signal for CNM-Au8® in Healey ALS Platform Trial

    The primary endpoint of adjusted ALSFRS-R and secondary endpoints of CAFS and SVC were not met at 24 weeksPrespecified exploratory analyses of the secondary survival endpoint for the 30 mg dose demonstrated a >90% reduction in risk of death or risk of death/permanently assisted ventilation at 24 weeks Survival signal consistent with prior results from the Phase 2 RESCUE-ALS trialClene will continue the open-label extension of CNM-Au8 in the Healey ALS Platform Trial and is in discussions with the Healey & AMG ALS Center to design and offer an Expanded Access Protocol (EAP) of CNM-Au8 30mg for eligible participants of closed regimens and othersClene is pursuing multiple paths, including ongoi

    10/3/22 8:00:00 AM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Clene to Report HEALEY ALS Platform Trial Topline Results on Monday, October 3

    SALT LAKE CITY, Sept. 30, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN) along with its subsidiaries "Clene" and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, today announced that it will report topline results of the CNM-Au8® regimen of the HEALEY ALS Platform Trial on Monday, Oct. 3. Clene's management team will host a conference call and webcast to discuss the results. Conference Call and Webcast DetailsTime and Date: 8:30 a.m. EDT on Oct. 3, 2022Investors: 1 (888) 660-6179 (toll-free) or 1 (929) 203-1946 (toll)Conference ID: 5318408Webcast Link A live audio

    9/30/22 4:12:25 PM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLNN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Clene Inc.

    SC 13G/A - Clene Inc. (0001822791) (Subject)

    11/14/24 3:32:55 PM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Clene Inc.

    SC 13G - Clene Inc. (0001822791) (Subject)

    11/14/24 3:26:45 PM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Clene Inc.

    SC 13D/A - Clene Inc. (0001822791) (Subject)

    10/2/24 4:38:44 PM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care